Skip to content

Perspective Therapeutics CATX Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Precigen logo
PrecigenPGEN
$48.77M-34.3%
PVL
Palvella TherapeuticsPVLA
$55.46M

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$28.3M-29.5%
Net income-$26.2M-44.1%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$54.0M+21.5%
Total debt$4.2M+10.9%
Total equity$347.4M+22.1%
Total assets$410.8M+24.7%

Cash flow

See full
Operating cash flow-$31.5M-45.8%
CapEx$6.9M+47.3%
Free cash flow-$38.3M-46.1%

Valuation

See full
Market cap$342.14M+33.2%
Enterprise value$292.34M+35.2%
P/S34.2×+19.6×

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp
FCF margin-1,073.3%

Returns & leverage

See full
Return on equity-35.2%+2.3pp
Debt / equity0.0×
Current ratio8.7×-8.3×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Perspective Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Perspective Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Perspective Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Perspective Therapeutics (CATX) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $216.96M in Q1 2026.
How has Perspective Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Perspective Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 29.7% year-over-year, from $167.3M to $216.96M.
What is the long-term trend for Perspective Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 3 years (2022 to 2025), Perspective Therapeutics's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 71.1% compound annual growth rate (CAGR), from $22.76M to $114.11M.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.